---
document_datetime: 2025-11-06 14:04:53
document_pages: 7
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/kymriah-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: kymriah-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.5988785
conversion_datetime: 2025-12-25 11:07:07.769682
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Kymriah

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IA /  | This was an application for a group of | 06/11/2025                          |                                             | Annex II and                     |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000309349                     | variations. B.II.c.1 Change in the specification parameters and/or limits of an excipient - B.II.c.1.c Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) - Accepted A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of   |            |     | PL   |                |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------|----------------|
| Variation type II / EMA/VR/0000284307 | B.II.b.3 Change in the manufacturing process of the finished product, including an                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 16/10/2025 | N/A |      | Not applicable |

<div style=\"page-break-after: always\"></div>

|                                          | intermediate used in the manufacture of the finished product - B.II.b.3.b Substantial changes to a manufacturing process that may have a significant impact on the quality, safety and efficacy of the medicinal product - Accepted                                                                                                                                                                                             |            |     |      |                                                                                                                                                                                                                                                    |
|------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IA_IN / EMA/VR/0000300811 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.z Change(s) in the Summary of product Characteristics, Labelling or Package Leaflet intended to implement the outcome of a PRAC signal recommendation: implementation of wording agreed by the competent authority that do not require any further assessment - Accepted                                                                                                      | 24/09/2025 |     | SmPC | To update section 4.4 of the SmPC to implement the signal recommendations on 'Ciltacabtagene autoleucel; idecabtagene vicleucel; tisagenlecleucel - Progressive multifocal leukoencephalopathy (EPITT No 20153)' adopted at the 10 July 2025 PRAC. |
| Variation type IB / EMA/VR/0000293714    | This was an application for a group of variations. B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.z Other variation - Accepted | 23/09/2025 | N/A |      |                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|                                       | parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.b Tightening of specification limits - Accepted B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.z - To more accurately describe the appearance of active substance, starting material, intermediate or reagent - Accepted   |            |     |                |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------|
| Variation type IB / EMA/VR/0000273730 | B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.a Minor change in the manufacturing process - Accepted                                                                                                                                                                                                                                                                                                                               | 20/06/2025 | N/A |                |
| Variation type II / EMA/VR/0000258240 | B.II.e.1.b Change in type of container or addition of a new container - B.II.e.1.b.2 Sterile medicinal products and biological/ immunological medicinal products - Accepted                                                                                                                                                                                                                                                                                                                                                                     | 22/05/2025 | N/A | Not applicable |
| Variation type II / EMA/VR/0000249024 | B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished                                                                                                                                                                                                                                                                                                                                                                                                                           | 25/04/2025 | N/A |                |

<div style=\"page-break-after: always\"></div>

|                                       | product - B.II.b.1.z Other changes - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |     |          |                |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------|----------------|
| Variation type II / EMA/VR/0000248534 | C.I.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.b Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment by the competent authority is required* - Accepted Submission of the interim report from study CCTL019H2301 / BELINDA, including final overall survival results, listed as an obligation in the Annex II of the Product Information. This is an open label, phase III PAES of Kymriah versus standard of care in adult patients with relapsed or refractory aggressive B cell non-Hodgkin lymphoma. | 25/04/2025 |     | Annex II | Not applicable |
| Variation type IB / EMA/VR/0000257168 | This was an application for a group of variations. B.I ACTIVE SUBSTANCE - B.I.z Other variation - Accepted B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.z                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 02/04/2025 | N/A |          |                |

<div style=\"page-break-after: always\"></div>

|                                       | Other variation - Accepted B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.z Other variation - Accepted                                                                                                                                                                                                  |            |     |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000244913 | This was an application for a group of variations. B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.e Other changes to a test procedure (including replacement or addition) for the active substance or a starting material/intermediate - Accepted B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.e Other changes to a test procedure (including replacement or | 17/02/2025 | N/A |

<div style=\"page-break-after: always\"></div>

| starting material/intermediate - Accepted   |
|---------------------------------------------|